Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories.
Miyuki HoshiMayumi MatsunagaKazutaka NogamiKana HamadaTaiga KoboriKeigo KainumaMizuho NagaoTakao FujisawaPublished in: Asia Pacific allergy (2020)
Real-world experience with mepolizumab for pediatric asthma is still limited. We report 3 patients who were treated with mepolizumab for severe adolescent asthma. Two patients, a 12-year-old boy and a 14-year-old girl, responded well to mepolizumab and showed apparent improvement in lung function from a downward trend over time before treatment. The third patient, a 16-year-old boy, whose treatment was switched from omalizumab to mepolizumab, did not have satisfactory response. The 2 successful cases had eosinophil counts of 440 and 371/μL and multiple comorbid allergic diseases including food allergies. The clinical benefit to them included elimination of both exacerbation and exercise-induced asthma. Interestingly, the boy's food-induced gastrointestinal symptoms disappeared following start of mepolizumab treatment.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- cystic fibrosis
- air pollution
- mental health
- newly diagnosed
- allergic rhinitis
- end stage renal disease
- early onset
- chronic kidney disease
- computed tomography
- climate change
- peritoneal dialysis
- human health
- high glucose
- replacement therapy
- oxidative stress
- peripheral blood
- mechanical ventilation
- childhood cancer